LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc...
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE...
Top-line results expected in 2Q 2021 LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona...
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc...
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
AIM 30 October 2020 NOTICE 30/10/2020 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON At the request of the Company the...
- clinical-stage biopharmaceutical company - Pretax loss in third quarter ended September 30 widens to USD22.2 millio ...
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients...
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the...
FTSE Russell 23 October 2020 Verona Pharma (UK): Constituent Deletion Changes in FTSE UK Index Series 23 October 2020 Subject to the expected...
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...
Posters highlight ensifentrine's potential to provide rapid benefits LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona...
LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...
- clinical-stage biopharmaceutical company - To cancel trading of shares on AIM market. Last day of trading October 2 ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads